Oxaliplatin: a review of preclinical and clinical studies.
about
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Role of Biomarkers in the Development of PARP InhibitorsThe X-ray structure of the complex formed in the reaction between oxaliplatin and lysozymeOxaliplatin vs. cisplatin: competition experiments on their binding to lysozymeRole of Deficient Mismatch Repair in the Personalized Management of Colorectal CancerFactors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patientsTernary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell linesPotential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseasesOxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum AccumulationA phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian CancerA phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatmentCurrent status of pharmacological treatment of colorectal cancer.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsUnusual DNA binding modes for metal anticancer complexes.Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathyAssociation between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapyOvercoming platinum resistance in ovarian carcinoma.Nanocarriers for delivery of platinum anticancer drugs.Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.The interaction of platinum-based drugs with native biologically relevant proteins.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH studyOxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer.Oxaliplatin: a review in the era of molecularly targeted therapyFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic OOxaliplatin. A platinum compound for colorectal cancer?An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.Novel treatments and therapies in development for pancreatic cancer.Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.An adsorptive transfer technique coupled with brdicka reaction to reveal the importance of metallothionein in chemotherapy with platinum based cytostatics.A retrospective study of first-line combination chemotherapy in advanced colorectal cancer: a Korean single-center experience.Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.
P2860
Q24658529-4565DCA6-0F47-40E9-8FA7-BEDD85D528D0Q26753159-5ABDDBD5-CB35-4E70-B538-07DD8A23853AQ27690763-FC2816CD-E4FF-4331-A696-3B7416B21682Q27700850-20D28936-1540-4DBA-AD50-7130693D0DBBQ28080176-E2C40EB3-138A-4EBA-A393-1772CF84E330Q28346039-6E8DCF76-A161-4DA0-A1E5-32B8EC32346EQ28350941-D40B9D2C-97A3-411E-9C17-C984AA1A2612Q28391383-3FCA45DF-6F97-4781-B30A-43362F0C9711Q28546867-71BC861D-880B-43DE-AC31-2C08AE7613E8Q33366008-E1A7EA74-57AC-43E6-93C2-3C5A437228D7Q33366782-AAEA0F97-9E57-4C7F-8D66-5F6DB8D3F736Q33368773-74AB679B-DD4A-413A-B941-BCBEC078BA08Q33370390-649F4F6D-2D5F-41F8-ADA8-D31E4FAE1B40Q33400294-DCF8F7EA-15EE-4785-B258-E748862E3D92Q33407256-8888CC73-6CBE-4B8D-B630-143790571A64Q33420154-5ECF2401-6E88-43FC-A1C6-FCF1F5C21471Q33634975-2877E817-58DB-48FA-870F-ECABB9A5B26BQ33651496-A7ABEB8D-B548-4C8F-BBD2-EAD70D0781F1Q33715042-8827A108-5DEB-43FE-9C5B-652A154D8029Q33759532-1E993806-29C3-4142-833A-6F7EEFFFB4A8Q34008793-2D5AC987-9C82-4F39-9138-BBE9487BCE9AQ34071185-C29AD731-ABAE-4B9D-A927-D21C8951FB63Q34133825-5A8DD8B2-481B-4E91-8BCB-F6672C4F6E42Q34143862-886D93F6-6A13-44F0-ABA5-335B9A7AAF4BQ34233273-5DDDE5B3-55A5-4831-8F07-875F9BB09EFEQ34338695-0BCBFE06-ABFC-453E-A1C6-AA04D7159D73Q34342186-E1C944A5-E148-43B7-859C-BC588C2BF7B5Q34439746-2142C7A0-9E65-4725-AC81-1052F66CD293Q34458029-59C26435-FB40-48A2-97A7-3EDDF30EE557Q34494728-B3DCA6BC-265D-4958-942E-0A55C32F8439Q34541434-396B0A0E-689A-4C58-A1BC-14EB48495503Q34565268-176D308F-4067-45DF-A6A7-A9FBB19E12E3Q34566202-C4A76EB5-74C0-4802-A617-A273DA965A9CQ34599030-40E7273F-35D3-4D69-BBA3-52A69BA4F4D4Q34653461-08C62763-F7CB-4893-B039-35AAC6B3FB20Q34660844-3130FA46-4689-4157-8EDB-C3A43990B178Q34733071-98A9F531-74AC-4C62-BA63-5B7F90FFDE7DQ35002247-2F86A0C7-E988-4DB3-8FD1-2E6F71A14262Q35113026-8EAAA3C4-B997-4CEF-946E-58123EFD5738Q35130636-610A5226-DEA8-4899-8741-6857977280BC
P2860
Oxaliplatin: a review of preclinical and clinical studies.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Oxaliplatin: a review of preclinical and clinical studies.
@en
Oxaliplatin: a review of preclinical and clinical studies.
@nl
type
label
Oxaliplatin: a review of preclinical and clinical studies.
@en
Oxaliplatin: a review of preclinical and clinical studies.
@nl
prefLabel
Oxaliplatin: a review of preclinical and clinical studies.
@en
Oxaliplatin: a review of preclinical and clinical studies.
@nl
P2093
P356
P1433
P1476
Oxaliplatin: a review of preclinical and clinical studies.
@en
P2093
P304
P356
10.1023/A:1008213732429
P577
1998-10-01T00:00:00Z